A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
Early indicators suggest that highly effective messenger RNA (mRNA) vaccinations (BNT 162b2 [Pfizer-BioNTech] and mRNA-1273 [NIH-Moderna]) are beginning to curb the coronavirus disease 2019 (COVID-19) pandemic that has already taken the lives of 3 million individuals worldwide. However, questions about vaccine effectiveness remain for individuals with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, who are frequently treated with immune suppression. An earlydoi:10.17615/2a83-d665 fatcat:kh7mx2wfuzgcbkfa5wc66o3c4a